Japanese Pharma Ono Taps Congruence's AI for Small Molecule Discovery
Osaka-based Ono Pharmaceutical has broadened its existing partnership with Montreal-based Congruence Therapeutics to include small molecule discovery programs in neurology and immunology. Financial terms were not disclosed.
The agreement builds on a 2024 oncology-focused collaboration, under which Congruence applied its Revenir platform to oncology targets, and grants Ono exclusive worldwide option rights to develop and commercialize candidates generated through Congruence’s computational platform.
Ono Pharmaceutical is a Japan-based drug developer focused on areas with unmet medical need, including oncology, immunology, and neurology. The company works with academic and biotechnology partners to advance new therapies and conducts its clinical development and commercial operations in the United States and Europe through its affiliate, Deciphera Pharmaceuticals.
The new scope covers multiple protein targets in neurology and immunology, areas identified by Ono as strategic priorities. Congruence will be responsible for generating small molecule modulators, while Ono retains the option to advance selected candidates through development, manufacturing, and commercialization.
Congruence Therapeutics is a computational biotechnology company developing small molecule drugs designed to restore abnormal protein function. Congruence is also a member of the OpenFold Consortium, a non-profit initiative developing open-source AI tools for protein structure prediction and drug discovery.
Congruence’s Revenir platform is a computational drug discovery system designed to account for the fact that proteins are not static structures but flexible molecules that change shape as they function. Instead of analyzing a single fixed protein structure, the platform models how proteins move and how disease-causing mutations alter their shape and surface properties.
Revenir analyzes surface features and multiple biophysical parameters by comparing mutated proteins with their normal counterparts to identify hidden or transient binding pockets, including allosteric and so-called cryptic sites that may not be visible in static models. It then predicts small molecules that could bind to these sites and stabilize the protein in a functional state, with the aim of correcting the underlying defect.
The system is positioned as an alternative to traditional high-throughput screening, prioritizing computational identification of candidate compounds before laboratory validation and progression into hit-to-lead development.
Congruence internal Revenir-powered pipeline includes programs targeting genetic obesity, GBA-associated Parkinson’s disease, and alpha-1 antitrypsin deficiency, alongside partnered programs in oncology and metabolic disease. Congruence's lead asset, CGX-926 in genetic obesity, is currently in IND-enabling studies.
The collaboration reflects continued large pharma interest in computationally driven discovery platforms aimed at identifying novel small molecule modulators against difficult protein targets across multiple therapeutic areas.
Other recent examples include:
- Takeda and Iambic multi-year technology and discovery collaboration where Takeda uses Iambic’s physics+AI platform to advance a set of small-molecule programs, initially in oncology and GI/inflammation.
- Helsinn Healthcare and InVirtuoLabs collaboration combining Helsinn’s proprietary small-molecule compound library with InVirtuoLabs’ generative AI platform to accelerate discovery of novel therapeutics.
Topic: Biotech Ventures
